Journal of Clinical Endocrinology & Metabolism, Vol 78, 1461-1466, Copyright © 1994 by Endocrine Society

ARTICLES

Genetic influences on type I collagen synthesis and degradation: further evidence for genetic regulation of bone turnover

A Tokita, PJ Kelly, TV Nguyen, JC Qi, NA Morrison, L Risteli, J Risteli, PN Sambrook and JA Eisman
Bone and Mineral Research Division, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales, Australia.

Circulating osteocalcin, a marker of bone formation, is under strong genetic influence, and this effect is related to the genetic influence on bone density. To examine genetic influences on bone turnover further, other markers of bone formation (serum carboxyterminal propeptide of type I procollagen, PICP), bone resorption (serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen, ICTP), and nonosseous connective tissue synthesis (serum aminoterminal propeptide of type III procollagen, PIIINP) were studied in 82 female twin pairs: 42 monozygotic (MZ) and 40 dizygotic (DZ) twin pairs (mean age, MZ; 48.4 yr; DZ; 45.6 yr). The intraclass correlation coefficients of MZ twin pairs, rMZ, for serum PICP (0.78) and serum ICTP (0.68) were significantly greater than the corresponding rDZ (0.31 and 0.36, respectively), but a genetic effect on serum PIIINP was not demonstrable. Within DZ twin pair differences in serum PICP predicted differences in lumbar spine bone density (r = -0.37); higher serum PICP levels indicating the twin with the lower lumbar spine bone density. Also within pair differences in serum ICTP and PICP predicted differences in bone density at the lumbar spine independent of serum osteocalcin. These data indicate that both synthesis and degradation of type I collagen are genetically determined and that this phenomenon is related to the genetic regulation of bone density.

This article has been cited by other articles:

				T. V. Nguyen Genetics of Osteoporosis: From Population Association to Individualized Prognosis of Fracture IBMS BoneKEy, June 1, 2008; 5(6): 212 - 221. [Full Text] [PDF]

				Y. Kikuchi, T. Imakiire, M. Yamada, T. Saigusa, T. Hyodo, T. Kushiyama, K. Higashi, N. Hyodo, K. Yamamoto, S. Suzuki, et al. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1593 - 1600. [Abstract] [Full Text] [PDF]

				A. E. Nelson, C. J. Howe, T. V. Nguyen, K.-C. Leung, G. J. Trout, M. J. Seibel, R. C. Baxter, D. J. Handelsman, R. Kazlauskas, and K. K. Ho Influence of Demographic Factors and Sport Type on Growth Hormone-Responsive Markers in Elite Athletes J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4424 - 4432. [Abstract] [Full Text] [PDF]

				P. Garnero, F. Munoz, O. Borel, E. Sornay-Rendu, and P. D. Delmas Vitamin D Receptor Gene Polymorphisms Are Associated with the Risk of Fractures in Postmenopausal Women, Independently of Bone Mineral Density J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4829 - 4835. [Abstract] [Full Text] [PDF]

				M. L. Gourlay and S. A. Brown Clinical Considerations in Premenopausal Osteoporosis Arch Intern Med, March 22, 2004; 164(6): 603 - 614. [Abstract] [Full Text] [PDF]

				J. A. Eisman Pharmacogenetics of the Vitamin D Receptor and Osteoporosis Drug Metab. Dispos., April 1, 2001; 29(4): 505 - 512. [Abstract] [Full Text]

				J. A. Eisman Genetics of Osteoporosis Endocr. Rev., December 1, 1999; 20(6): 788 - 804. [Abstract] [Full Text]

				T D Spector, R W Keen, N K Arden, N A Morrison, P J Major, T V Nguyen, P J Kelly, J R Baker, P N Sambrook, J S Lanchbury, et al. Influence of vitamin D receptor genotype on bone mineral density in postmenopausal women: a twin study in Britain BMJ, May 27, 1995; 310(6991): 1357 - 1360. [Abstract] [Full Text]